An Emerging Treatment Alternative for Anemia in Chronic Kidney Disease Patients: A Review of Daprodustat

This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2018-01, Vol.35 (1), p.5-11
Hauptverfasser:	Becker, Kimberly A., Jones, John J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anemia - drug therapy Anemia - etiology Barbiturates - administration & dosage Barbiturates - adverse effects Barbiturates - therapeutic use Cardiology Clinical Trials, Phase III as Topic Endocrinology Erythropoietin - therapeutic use Glycine - administration & dosage Glycine - adverse effects Glycine - analogs & derivatives Glycine - therapeutic use Health technology assessment Humans Internal Medicine Medicine Medicine & Public Health Oncology Pharmacology/Toxicology Renal Dialysis Renal Insufficiency, Chronic - complications Review Rheumatology United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	This article reviews an emerging therapeutic agent, which is currently in phase III development for the treatment of anemia secondary to chronic kidney disease, covering promising phase II results, drug characteristics, and the current phase III trials, which, if approved, may significantly impact the management of anemia in this patient population.
ISSN:	0741-238X 1865-8652
DOI:	10.1007/s12325-017-0655-z